Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good evening, everyone. Thanks for joining us on day 3 of our Healthcare Conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley.
Delighted to have Akoya join us today. And representing the company, we have Brian McKelligon, CEO; and Joe Driscoll, CFO. So welcome, gents. Before we get started, a quick disclosure statement to read. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures.
If you have any questions, please do reach out to your sales rep. So Brian, I mean, before we get into the weeds, I mean, just for folks not as familiar with the story, could you provide a brief overview of the history of the company, how the 2 parts of the portfolio sort of like came together. And a highlight what you view as some of the key milestones you've achieved over the last 12 months or so besides the IPO, of course.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |